Efficacy and safety of low-dose everolimus in Chinese HR-positive, HER2-negative metastatic breast cancer patients.

被引：1
|
作者：
Shao, Xiying
Zheng, Yabing
Chen, Zhan-Hong
Li, Guangliang
Jia, Wang Xiao
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e13035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13035
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
    Ascione, Liliana
    Zagami, Paola
    Nicolo, Eleonora
    Crimini, Edoardo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (11):
  • [42] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Okazaki, Misato
    Horimoto, Yoshiya
    Tanabe, Masahiko
    Ichikawa, Yuko
    Tokuda, Emi
    Arakawa, Atsushi
    Kobayashi, Toshiyuki
    Saito, Mitsue
    MEDICAL ONCOLOGY, 2018, 35 (04)
  • [43] Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer
    Gaudio, M.
    Jacobs, F.
    Benvenuti, C.
    Saltalamacchia, G.
    Gerosa, R.
    De Sanctis, R.
    Santoro, A.
    Zambelli, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (03) : 487 - 495
  • [44] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Misato Okazaki
    Yoshiya Horimoto
    Masahiko Tanabe
    Yuko Ichikawa
    Emi Tokuda
    Atsushi Arakawa
    Toshiyuki Kobayashi
    Mitsue Saito
    Medical Oncology, 2018, 35
  • [45] Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
    Stefania Morganti
    Antonio Marra
    Edoardo Crimini
    Paolo D’Amico
    Paola Zagami
    Giuseppe Curigliano
    Breast Cancer Research and Treatment, 2022, 192 : 465 - 484
  • [46] A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
    Noguchi, Emi
    Yamanaka, Takashi
    Mukai, Hirofumi
    Yamamoto, Naohito
    Chung, Chi-Feng
    Lu, Yen-Shen
    Chang, Dwan-Ying
    Sohn, Joohyuk
    Kim, Gun Min
    Lee, Kyung-Hun
    Lee, Soo-Chin
    Iwasa, Tsutomu
    Iwata, Hiroji
    Watanabe, Kenichi
    Jung, Kyung Hae
    Tanabe, Yuko
    Kang, Seok Yun
    Yasojima, Hiroyuki
    Aogi, Kenjiro
    Tokunaga, Eriko
    Sim, Sung Hoon
    Yap, Yoon Sim
    Matsumoto, Koji
    Tseng, Ling-Ming
    Umeyama, Yoshiko
    Sudo, Kazuki
    Kojima, Yuki
    Hata, Tomomi
    Kuchiba, Aya
    Shibata, Taro
    Nakamura, Kenichi
    Fujiwara, Yasuhiro
    Tamura, Kenji
    Yonemori, Kan
    NPJ BREAST CANCER, 2024, 10 (01)
  • [47] Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer
    M. Gaudio
    F. Jacobs
    C. Benvenuti
    G. Saltalamacchia
    R. Gerosa
    R. De Sanctis
    A. Santoro
    A. Zambelli
    Breast Cancer Research and Treatment, 2024, 203 : 487 - 495
  • [48] Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
    Morganti, Stefania
    Marra, Antonio
    Crimini, Edoardo
    D'Amico, Paolo
    Zagami, Paola
    Curigliano, Giuseppe
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (03) : 465 - 484
  • [49] Incidence of HER2-low Expression in HR-positive/HER2-negative and Triple-Negative Breast Cancers in the Integra Connect Database
    Fares, Marielle
    Gart, Mike
    Blanc, Simon
    Zheng, Jia
    Saunders, William
    Smith, Robert
    Vasudevan, Anupama
    English, Sandy
    CANCER RESEARCH, 2023, 83 (05)
  • [50] Survival is associated with repressive histone trimethylation markers in both HR-positive HER2-negative and triple-negative breast cancer patients
    Bo Wang
    Meng Zhou
    Yue-yu Shi
    Xing-lei Chen
    Yue-xiang Ren
    Yuan-zhong Yang
    Lu-ying Tang
    Ze-fang Ren
    Virchows Archiv, 2023, 482 : 1047 - 1056
12345